探讨奥美沙坦酯氢氯噻嗪片联合硝苯地平缓释片治疗高血压的临床效果  

The clinical effect of olmesartan medoxomil and hydrochlorothiazide tablets combined with nifedipine sustained-release tablets in the treatment of hypertension

作　　者：乔金文 QIAO Jin-wen(Department of Cardiology,Yutai County People's Hospital,Jining 272300,China)

机构地区：[1]鱼台县人民医院心内科,272300

出　　处：《中国实用医药》2024年第17期10-13,共4页China Practical Medicine

摘　　要：目的分析奥美沙坦酯氢氯噻嗪片+硝苯地平缓释片治疗高血压的效果。方法88例高血压患者,随机分为对照组和观察组,每组44例。对照组给予常规对症治疗(硝苯地平缓释片),观察组在对照组的治疗基础上联合奥美沙坦酯氢氯噻嗪片治疗。比较两组患者治疗效果、血压、心功能指标、生活质量、不良反应发生情况。结果观察组患者治疗总有效率97.73%高于对照组的72.73%(P<0.05)。治疗后,观察组患者舒张压(82.15±2.12)mm Hg(1 mm Hg=0.133 kPa)、收缩压(125.27±3.09)mm Hg低于对照组的(87.32±7.15)、(141.29±8.47)mm Hg(P<0.05)。治疗后,观察组患者左心室壁厚度(9.26±0.56)mm、室间隔厚度(9.85±0.82)mm、左心室舒张末期内径(43.20±1.09)mm、左心室质量指数(117.28±12.09)g/m^(2)均低于对照组的(11.26±2.30)mm、(13.20±2.20)mm、(48.56±4.20)mm、(138.56±32.20)g/m^(2)(P<0.05)。治疗后,观察组患者活力状况评分(75.49±2.36)分、生理职能评分(75.93±2.08)分、情感职能评分(74.82±2.16)分、社会功能评分(74.82±2.09)分高于对照组的(62.59±8.15)、(62.39±8.26)、(62.39±8.26)、(62.39±8.22)分(P<0.05)。两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论在治疗高血压时,采取奥美沙坦酯氢氯噻嗪片+硝苯地平缓释片的方案,疗效显著,对患者血压与心功能指标的改善效果均较好,还可提升患者的生活质量,安全性较高。Objective To analyze the effect of olmesartan medoxomil and hydrochlorothiazide tablets combined with nifedipine sustained-release tablets in the treatment of hypertension.Methods 88 patients with hypertension were randomly divided into a control group and an observation group,with 44 cases in each group.The control group was given conventional symptomatic treatment(nifedipine sustained-release tablets),and the observation group was given olmesartan medoxomil and hydrochlorothiazide tablets on the basis of the control group.The therapeutic effect,blood pressure,cardiac function indicators,quality of life and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of 97.73%in the observation group was higher than 72.73%in the control group(P<0.05).After treatment,the observation group had diastolic blood pressure of(82.15±2.12)mm Hg(1 mm Hg=0.133 kPa)and systolic blood pressure of(125.27±3.09)mm Hg,which were lower than(87.32±7.15)and(141.29±8.47)mm Hg in the control group(P<0.05).After treatment,the observation group had left ventricular wall thickness of(9.26±0.56)mm,ventricular septal thickness of(9.85±0.82)mm,left ventricular end-diastolic diameter of(43.20±1.09)mm,and left ventricular mass index of(117.28±12.09)g/m2,which were lower than(11.26±2.30)mm,(13.20±2.20)mm,(48.56±4.20)mm,and(138.56±32.20)g/m2 in the control group(P<0.05).After treatment,the scores of vitality,physical functioning,emotional functioning and social functioning of the observation group were(75.49±2.36),(75.93±2.08),(74.82±2.16)and(74.82±2.09)points,which were higher than(62.59±8.15),(62.39±8.26),(62.39±8.26)and(62.39±8.22)points of the control group(P<0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of hypertension,the regimen of olmesartan medoxomil and hydrochlorothiazide tablets+nifedipine sustained-release tablets has significant efficacy,and has good improvement on patients'bloo

关 键 词：奥美沙坦酯氢氯噻嗪片 硝苯地平缓释片 高血压 

分 类 号：R544.1[医药卫生—心血管疾病]